PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
PDS Biotechnology Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.92−0.21 (-18.89%)
Close on Oct 19, 2026
- Market cap
- $51.01M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0098 (−1.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $51.01M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -54.40%
Fundamentals
- Net income
- -$33.67M
- EPS, diluted
- -$0.65
- Free cash flow
- -$27.75M
- Book value per share
- -$0.06
- Diluted shares
- 56M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Operating income
-$27.83M
Net income
-$33.67M
EPS, diluted
-$0.65
Free cash flow
–
Reported periodTrailing twelve months